Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) has announced that the initial order of its updated Venowave product has been shipped to its US distributor, DME Authority, LLC, from its Chinese contract manufacturer, despite the challenges of material and component shortages, logistics and shipping delays and lockdowns in various parts of China.
The company reminded investors that the initial order consists of 2,500 units, each consisting of two Venowave devices, of which 500 units have been shipped by air, with the balance being shipped by sea.
"It has been a frustrating process with all of the shortages and delays, but we are now poised to increase production and availability of the product as demand grows,” the company’s CEO Rob Fia said in a statement. “We are excited to be able to deliver products to customers in the US who have been patiently waiting for this potential life saving technology."
READ: Therma Bright submits its AcuVid COVID-19 Rapid Antigen Saliva test application for FDA Emergency Use Authorization
Venowave is a compact and lightweight Deep Vein Thrombosis (DVT) prevention pump specifically designed for use at home. The Venowave device uses a continuous wave motion to increase blood flow in the veins. The increased blood circulation helps prevent venous stasis, which is a major contributor in thrombus formation.
Specifically, Therma Bright said the device imitates the body's venous system to counteract the pooling of blood in the lower extremities which can lead to clotting. With about 50% of DVTs beginning to form intra-operatively and 75% forming within 48 hours post-operatively, it said the technology is pioneering an alternative, easy-to-use life-saving treatment for this condition.
Therma Bright is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges.
The company's initial breakthrough proprietary technology delivers effective, non-invasive, and pain-free skincare.
Contact the author at stephen.gunnion@proactiveinvestors.com